AMARIN CORP PLC\UK Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock
AMARIN CORP PLC\UK (AMRN) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock of 6.99 million shares for the 3-month period ending 2020-06-30, per its 10-Q filed 2021-08-05.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock · last filed 2021-08-05
- AMARIN CORP PLC\UK incremental common shares attributable to dilutive effect of conversion of preferred stock for the quarter ending 2020-06-30 was 6.99M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock 3 month |
|---|---|
| 2020-06-30 | 6.99M shares 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |